Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Subscribe To Our Newsletter & Stay Updated